Actos Lawyers
If you have taken Actos and you are concerned about your health, promptly consult your physician for an evaluation to discuss whether alternatives to Actos are an option.
If you have suffered side effects after taking Actos, you may be entitled to compensation. You should act immediately to contact an attorney experienced in matters involving dangerous pharmaceuticals.
O’Steen MacLeod Combs PLC is recognized by Best Lawyers as one of the top law firms in America. Our firm was designated as a Tier 1 law firm in Personal Injury Litigation in the organization’s “Best Law Firms” rankings for 2025.
For more than 50 years, our lawyers have assisted victims of medical malpractice receive everything they deserve for their losses.
RECORD SETTING
$5 billion
recovered
for our
clients
LARGEST LANDMARK CASE
IN HISTORY
SELECTED BY
ARIZONA
ATTORNEY
GENERAL
TO FIGHT
AGAINST BIG TOBACCO
AND WON
Actos Lawsuit
MDL Panel Considering Consolidation of Actos Lawsuits
October 20, 2011—The U.S. Judicial Panel on Multidistrict Litigation is considering a petition to consolidate all federal Actos cases before a single judge. The request, initially made by attorneys representing Actos victims, asked that all federal cases be transferred to the Southern District of Illinois.
Takeda Pharmaceuticals, the manufacturer of Actos, agrees that the Actos bladder cancer lawsuits should be consolidated for coordinated pretrial management, but proposes the cases proceed in either the Northern District of Illinois or Western District of Illinois.
MDL proceedings resemble class action lawsuits and allow for the efficient resolution of large numbers of cases involving similar issues. If the MDL is established, every federal case will be transferred to the selected venue. Actos lawsuits filed in state courts would be unaffected by the move.
A hearing has been scheduled for December 1, 2011 to consider the motion to consolidate Actos bladder cancer lawsuits.
Actos Increases Risk of Eye Disease, Blindness
June 26, 2011—A study presented at the annual meeting for the American Diabetes Association concluded that patients taking Actos are at a significantly increased risk for developing diabetic macular edema, a serious eye disease that can lead to blindness.
The study involved more than 100,000 people and found that Actos patients were up to six times more likely to develop the eye disease. The results come less than two weeks after the FDA announced a connection between Actos and bladder cancer.
Ongoing Study Links Actos to Bladder Cancer
June 16, 2011—The FDA warned Actos patients that long-term use of the drug may be associated with bladder cancer. An ongoing study has revealed that people taking the drug for more than one year have an increased risk of developing bladder cancer. The FDA announcement came just days after Germany and France banned sale of the drug.
The FDA has been monitoring Actos for this risk since September 2010 and will continue assessing the safety of the drug.
Our Awards
For a free, confidential case evaluation: